FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604368054> ?p ?o ?g. }

• W2604368054 endingPage "58303" @default.
• W2604368054 startingPage "58292" @default.
• W2604368054 abstract "The impact of pharmacogenetics on predicting survival in diffuse large B-cell lymphoma (DLBCL) remains unclear. We tested 337 DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 9 single nucleotide polymorphisms from 6 genes (CD20, FCGR2A, NAD(P)H, ABCC2, ABCG2 and CYP3A5). Patients who carried the NCF4 rs1883112 GG genotype showed significantly shorter progression-free survival (PFS) (P = 0.023) and event-free survival (EFS) (P < 0.001) comparing with A allele. A significantly shortened PFS (P = 0.013) and EFS (P = 0.002) was also observed in the patients with ABCG2 rs2231137 GG genotype. Furthermore, the elder (> 60 years old) or male patients with ABCG2 rs2231137 GG genotype had poorer PFS and EFS than A allele. Moreover, CD20 rs2070770 CC and RAC2 rs13058338 AT genotypes were independent predictors of chemotherapy-induced toxicity. Cox proportional hazards analyses demonstrated that the GG genotype of ABCG2 rs2231137 and NCF4 rs1883112 were risk factors in DLBCL patients. In conclusion, the identified polymorphisms provide guide for the identification of DLBCL patients who are likely to benefit from chemotherapy." @default.
• W2604368054 created "2017-04-14" @default.
• W2604368054 creator A5000444143 @default.
• W2604368054 creator A5014567045 @default.
• W2604368054 creator A5029000600 @default.
• W2604368054 creator A5037257799 @default.
• W2604368054 creator A5043061605 @default.
• W2604368054 creator A5049603443 @default.
• W2604368054 creator A5053620278 @default.
• W2604368054 creator A5058747734 @default.
• W2604368054 creator A5079434327 @default.
• W2604368054 date "2017-04-06" @default.
• W2604368054 modified "2023-10-18" @default.
• W2604368054 title "<i>ABCG2</i> and <i>NCF4</i> polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP" @default.
• W2604368054 cites W1504187995 @default.
• W2604368054 cites W1555292656 @default.
• W2604368054 cites W1912693401 @default.
• W2604368054 cites W1938484148 @default.
• W2604368054 cites W1980132014 @default.
• W2604368054 cites W1981670631 @default.
• W2604368054 cites W1983519619 @default.
• W2604368054 cites W1985346980 @default.
• W2604368054 cites W1989994240 @default.
• W2604368054 cites W2006104752 @default.
• W2604368054 cites W2012977510 @default.
• W2604368054 cites W2031718974 @default.
• W2604368054 cites W2032685816 @default.
• W2604368054 cites W2047384307 @default.
• W2604368054 cites W2048729835 @default.
• W2604368054 cites W2053162975 @default.
• W2604368054 cites W2058015212 @default.
• W2604368054 cites W2063163336 @default.
• W2604368054 cites W2086998282 @default.
• W2604368054 cites W2087824134 @default.
• W2604368054 cites W2092251589 @default.
• W2604368054 cites W2095955743 @default.
• W2604368054 cites W2097790191 @default.
• W2604368054 cites W2101799341 @default.
• W2604368054 cites W2106926141 @default.
• W2604368054 cites W210951708 @default.
• W2604368054 cites W2111988435 @default.
• W2604368054 cites W2116678763 @default.
• W2604368054 cites W2119443549 @default.
• W2604368054 cites W2121074897 @default.
• W2604368054 cites W2122091781 @default.
• W2604368054 cites W2122443843 @default.
• W2604368054 cites W2129375438 @default.
• W2604368054 cites W2129844899 @default.
• W2604368054 cites W2143464740 @default.
• W2604368054 cites W2147757009 @default.
• W2604368054 cites W2153665789 @default.
• W2604368054 cites W2158267770 @default.
• W2604368054 cites W2158372560 @default.
• W2604368054 cites W2160305510 @default.
• W2604368054 cites W2160460198 @default.
• W2604368054 cites W2165901843 @default.
• W2604368054 cites W2212886038 @default.
• W2604368054 cites W2274742087 @default.
• W2604368054 cites W4205736005 @default.
• W2604368054 cites W4255357812 @default.
• W2604368054 doi "https://doi.org/10.18632/oncotarget.16869" @default.
• W2604368054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5601652" @default.
• W2604368054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28938556" @default.
• W2604368054 hasPublicationYear "2017" @default.
• W2604368054 type Work @default.
• W2604368054 sameAs 2604368054 @default.
• W2604368054 citedByCount "6" @default.
• W2604368054 countsByYear W26043680542020 @default.
• W2604368054 countsByYear W26043680542022 @default.
• W2604368054 crossrefType "journal-article" @default.
• W2604368054 hasAuthorship W2604368054A5000444143 @default.
• W2604368054 hasAuthorship W2604368054A5014567045 @default.
• W2604368054 hasAuthorship W2604368054A5029000600 @default.
• W2604368054 hasAuthorship W2604368054A5037257799 @default.
• W2604368054 hasAuthorship W2604368054A5043061605 @default.
• W2604368054 hasAuthorship W2604368054A5049603443 @default.
• W2604368054 hasAuthorship W2604368054A5053620278 @default.
• W2604368054 hasAuthorship W2604368054A5058747734 @default.
• W2604368054 hasAuthorship W2604368054A5079434327 @default.
• W2604368054 hasBestOaLocation W26043680541 @default.
• W2604368054 hasConcept C104317684 @default.
• W2604368054 hasConcept C126322002 @default.
• W2604368054 hasConcept C135763542 @default.
• W2604368054 hasConcept C143998085 @default.
• W2604368054 hasConcept C2776694085 @default.
• W2604368054 hasConcept C2776755627 @default.
• W2604368054 hasConcept C2778559949 @default.
• W2604368054 hasConcept C2779338263 @default.
• W2604368054 hasConcept C2779429289 @default.
• W2604368054 hasConcept C2779725641 @default.
• W2604368054 hasConcept C2780653079 @default.
• W2604368054 hasConcept C2780739268 @default.
• W2604368054 hasConcept C50382708 @default.
• W2604368054 hasConcept C54355233 @default.
• W2604368054 hasConcept C55775858 @default.
• W2604368054 hasConcept C71924100 @default.
• W2604368054 hasConcept C86803240 @default.
• W2604368054 hasConcept C90924648 @default.

• next